Business
-
Daiichi Sankyo has begun marketing its single dose Inavir laninamivir octanoate DPI for the treatment of influenza in Japan. According to the company, it plans to supply a total of 4 million units for the… Read more . . .
-
Particle analysis company ChemImage has launched a new testing and consulting business called Gateway Analytical, based in Gibsonia, Pennsylvania. Gateway offers particle characterization using various spectroscopic and microscopic techniques, as well as regulatory consulting. Read… Read more . . .
-
A group of investors led by Vatera Healthcare Partners has added $69 million to Pearl Therapeutics’s funding, bringing the total to more than $102 million since 2007. Pearl’s lead candidate, PT003, a glycopyrrolate/formoterol MDI for… Read more . . .
-
Pfizer says that it is "reviewing strategic alternatives" for its Capsugel business and that divestiture is an option. Capsugel manufactures capsules, including Vcaps hypromellose capsules for inhalation applications, and the Xcelodose powder dispensing system. 2009… Read more . . .
-
US eye care company ISTA Pharmaceuticals announced plans to file an investigational new drug (IND) application with the FDA for its bepotastine besilate nasal spray for the treatment of seasonal allergic rhinitis by the end… Read more . . .
-
US biotech company Generex has announced that the Canadian Intellectual Property Office has granted its patent titled "Pharmaceutical Compositions for Buccal and Pulmonary Application." Generex develops formulations for buccal delivery using its RapidMist metered dose… Read more . . .
-
Shareholders of pharma companies Biovail and Valeant voted to approve their merger, and the new company is now called Valeant Pharmaceuticals International. Valeant markets Migranal dihydroergotamine nasal spray in the US, and Biovail had been… Read more . . .
-
According to Stirling Products, the company is in discussions with several major pharmaceutical companies about partnerships on products using its patented high density aerosol (HDA) device. The company says that its ultrasound-based HDA technology produces… Read more . . .
-
Boston Scientific has acquired Asthmatx, the developer of a bronchial thermoplasty procedure marketed as an alternative to inhaled medications for the treatment of severe asthma for an upfront payment of $193.5 million and future payments… Read more . . .
-
Quintiles has announced that it will provide commercialization services to Pharmaxis for the launch of Pharmaxis’s Bronchitol mannitol DPI for the treatment of Cystic Fibrosis. Bronchitol has received orphan drug status in both Europe and… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK